Intranasal, multivalent SARS-CoV-2 vaccine

The emergence of SARS-CoV-2 variants during the COVID-19 pandemic has demonstrated a need for broad immunization, such as provided by multivalent vaccines. In response, Stanford researchers have formulated a SARS-CoV-2 vaccine that allows delivery of all the SARS-CoV-2 surface antigens or multiple antigen variants, in order to provide broader protection than the monovalent vaccines currently in emergency use.

The researchers have leveraged their recently developed gold-polymer nanoparticles (see 'Publications') to carry eight SARS-CoV-2 mRNAs and proteins. The particles can be delivered to the respiratory mucosa via intranasal administration for specific immunization of the initial site of SARS-CoV-2 infection.

Stage of development

Proof-of-concept. The researchers have demonstrated nanoparticle delivery and generic mRNA expression in mouse lung via intranasal administration. They have formulated nanoparticles loaded with both mRNAs and proteins for all four SARS-CoV-2 surface antigens.